103 related articles for article (PubMed ID: 20231035)
21. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Jensen LO; Thayssen P; Hansen HS; Christiansen EH; Tilsted HH; Krusell LR; Villadsen AB; Junker A; Hansen KN; Kaltoft A; Maeng M; Pedersen KE; Kristensen SD; Bøtker HE; Ravkilde J; Sanchez R; Aarøe J; Madsen M; Sørensen HT; Thuesen L; Lassen JF;
Circulation; 2012 Mar; 125(10):1246-55. PubMed ID: 22308301
[TBL] [Abstract][Full Text] [Related]
22. Do the benefits outweigh the risks with drug-eluting stents?
Kløw NE
Scand Cardiovasc J; 2007 Jan; 41(1):8-9. PubMed ID: 17365970
[No Abstract] [Full Text] [Related]
23. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
Brilakis ES; Banerjee S
Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
[No Abstract] [Full Text] [Related]
24. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
[TBL] [Abstract][Full Text] [Related]
25. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
26. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
De Luca G; Dirksen MT; Spaulding C; Kelbaek H; Schalij M; Thuesen L; van der Hoeven B; Vink MA; Kaiser C; Musto C; Chechi T; Spaziani G; Díaz de la Llera LS; Pasceri V; Di Lorenzo E; Violini R; Cortese G; Suryapranata H; Stone GW;
Arch Intern Med; 2012 Apr; 172(8):611-21; discussion 621-2. PubMed ID: 22529227
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
28. Coronary stent strut fracture after drug-eluting stent implantation: a newly recognized complication.
Celik T; Iyisoy A; Dogru MT; Isik E
Int J Cardiol; 2009 Feb; 132(1):121-2. PubMed ID: 17692950
[TBL] [Abstract][Full Text] [Related]
29. Medial necrosis due to sirolimus-eluting stent implantation in human coronary artery.
Inoue K; Mitsudo K; Nobuyoshi M
J Cardiol; 2008 Feb; 51(1):60-4. PubMed ID: 18522776
[TBL] [Abstract][Full Text] [Related]
30. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis.
Bavry AA; Bhatt DL
Lancet; 2008 Jun; 371(9630):2134-43. PubMed ID: 18572082
[TBL] [Abstract][Full Text] [Related]
31. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
33. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
34. The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.
Huang Y; Venkatraman SS; Boey FY; Umashankar PR; Mohanty M; Arumugam S
J Interv Cardiol; 2009 Oct; 22(5):466-78. PubMed ID: 19627432
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis.
Piccolo R; Galasso G; Piscione F; Esposito G; Trimarco B; Dangas GD; Mehran R
Am J Cardiol; 2014 Nov; 114(9):1339-46. PubMed ID: 25242363
[TBL] [Abstract][Full Text] [Related]
37. Drug eluting stents in patients with diabetes.
Agostoni P; Van den Branden F
BMJ; 2008 Aug; 337():a1359. PubMed ID: 18757997
[No Abstract] [Full Text] [Related]
38. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
[TBL] [Abstract][Full Text] [Related]
39. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
Vaina S; Ong AT; Serruys PW
Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
